Below are Gilead’s Research Scholar Program Hematologic Malignancies Awardees and their research titles. As the program values diverse voices and innovative research topics to address areas of unmet medical need, you do not need to duplicate previous research topics in order to be successful for an Award.
2022 Recipients
Teresa Sadras, PhD
University of Melbourne
Melbourne, Australia
"Investigating mechanistic basis of therapy-resistance in high-risk acute lymphoblastic leukemia"
Steven Ngo, PhD
Francis Crick Institute
London, England
"Investigating bone marrow niche contribution to leukemogenesis and therapy resistance"
Mikko Myllymäki, MD, PhD
University of Helsinki
Helsinki, Finland
"The clinical impact of clonal hematopoiesis and circulating tumor DNA in high-risk lymphoma"
2021 Recipients
Héléne Gleitz, PhD
Erasmus Medical Center
Rotterdam, The Netherlands
"Understanding the monocyte-stromal cell crosstalk in myeloproliferative neoplasms"
Lingwen Ding, PhD
National University of Singapore
Singapore
"Investigating the tumor suppressive role of mRNA decay activator ZFP36L1"
Monica Casucci, PhD
IRCCS San Raffaele Scientific Institute
Italy
"Exploiting glycosylation blockade to boost the efficacy of CD19 CAR-T cells against B-cell malignancies"
2019 Recipients
Lina Benajiba, MD, PhD
Hôpital Saint-Louis
Paris, France
"In vivo humanized bone marrow functional screening to identify microenvironment-related therapeutic targets in AML"
Charles De Bock, PhD
Children's Cancer Institute University of New South Wales
New South Wales, Australia
"Long read sequencing to characterize the alternatively spliced transcriptome downstream of mutant JAK3 signaling in T-cell acute lymphoblastic leukemia"
Margherita Ghisi, PhD
Cancer Research Center of Toulouse
Toulouse, France
"Investigating the role of alternative splicing in metabolism and therapy resistance of AML"
2018 Award Recipients
Yoshikane Kikushige, MD, PhD
Kyushu University
Fukuoka, Japan
"Elucidating a BCR-Mediated Positive Feedback Loop that Confers Survival of Chronic Lymphocytic Leukemia Cells"
Giovanni Roti, MD, PhD
University of Parma
Parma, Italy
"Targeting Atypical Protein Kinases in T Cell Acute Lymphoblastic Leukemia”
*RSP has been awarded but not funded due to unforeseeable circumstances not accountable to the investigator or his research team
Fatih Kocabas, PhD
Yeditepe University
Istanbul, Turkey
"Development of Small Molecule MEIS Inhibitors for Mitigating Cancer Growth"
2017 Award Recipients
Dominik Beck, PhD
University of New South Wales
Sydney, Australia
“Targeting Leukaemia-Specific Regulatory Elements for the Treatment of Intermediate- and High-Risk Patients”
Benjamin Cao, PhD
Commonwealth Scientific and Industrial Research Organisation
Clayton, Australia
“Chemosensitization of Drug-Resistant Acute Leukemia Using a Small Molecule Integrin Antagonist”
Javier Redondo-Muñoz, PhD
University Complutense of Madrid
Madrid, Spain
“Unraveling Histone Modifications as Therapeutic Targets Against Leukemic Cell Migration”
2016 Award Recipients
Teresa Ezponda, PhD
Center for Applied Medical Research
Pamplona, Spain
"Deciphering the Role of IncRNAs in Multiple Myeloma"
Daniel J. Hodson, MD, PhD
University of Cambrigde
Cambridge, UK
"Developing New Models for the Functional Investigation of Lymphoma"
Hidekazu Nishikii, MD, PhD
University of Tsukuba
Ibaraki, Japan
"Molecular Basis for the Involvement of Bone Marrow Microenvironment in Myelodysplastic Syndromes and Acute Myeloid Leukemia"
2015 Award Recipients
Raphael Itzykson, MD, PhD
Hopital Saint-Louis
Paris, France
"Clinical Relevance of Leukemia Stem Cell Diversity"
D. Michiel Pegtel, PhD
VUmc University Medical Center Cancer Center
Amsterdam The Netherlands
"Discovery of Lymphoma-Associated miRNA Variants by RNA Sequencing in Blood and CSF of Lymphoma Patients"
- GILEAD and the GILEAD logo are registered
- trademarks of Gilead Sciences, Inc., or one of its related companies. Kite
- and the Kite Logo are registered trademarks of Kite, a Gilead company.
- © 2022 Gilead Sciences, Inc. All rights reserved.
- November 2022, IHQ-UNB-2912